Exhibit 99.2
RESPIRONICS COMPLETES ACQUISITION OF NOVAMETRIX MEDICAL SYSTEMS

PITTSBURGH, Apr 15, 2002 /PRNewswire-FirstCall via COMTEX/ -- Respironics, Inc.
(Nasdaq: RESP), announced today that it has completed its previously announced
acquisition of Novametrix Medical Systems (previously Nasdaq/NMS Symbol: NMTX),
a leading cardiorespiratory monitoring company. As a result of the acquisition,
Novametrix has become a wholly owned subsidiary of Respironics. Combined
revenues of the two companies totaled approximately $502 million.

The tax-free, stock-for-stock transaction was valued at approximately $85
million. Under the terms of the merger, Novametrix stockholders received 0.2541
shares of Respironics common stock for each share of Novametrix common stock.
The exchange ratio was determined based on the weighted-average selling price of
$31.48 for Respironics common stock for the 20-day trading period from March 11
through April 8, 2002. Novametrix stockholders received Respironics stock in an
amount equal to $8.00 per Novametrix share based upon the weighted average
selling price. After accounting for the proceeds of warrant and option
exercises, additional Respironics shares issued in connection with the
transaction will total approximately 2,530,000. As of the close of trading on
April 12, 2002, Novametrix' common stock ceased to be traded on the Nasdaq
National Market and shareholders of Novametrix have become shareholders of
Respironics.

James W. Liken, President and CEO of Respironics said, "We are very excited
about the acquisition of Novametrix Medical Systems, which enhances the breadth
of our products and services, strengthens our infrastructure and positions us
to better serve our customers in the hospital marketplace. Novametrix has a long
history of innovation in cardiorespiratory monitoring technologies, which blend
well with our hospital therapeutic product offerings. In addition, the
developmental care products and services offered through Novametrix' Children's
Medical Ventures unit will augment our Homecare Division's infant management
business."

Parker/Hunter Incorporated acted as financial advisor and Reed Smith LLP acted
as legal counsel to Respironics in connection with the acquisition of
Novametrix.

Respironics, the global resource in the respiratory medical device industry,
provides innovative and unique programs to health care providers while helping
them to grow and manage their business efficiently. The company's focus is on
homecare, hospital and international markets, providing programs that manage
sleep disordered breathing, chronic obstructive pulmonary disease, asthma,
allergies and sinusitis, infant jaundice and apnea, heart failure and
restrictive lung disorders. Globally positioned, the company employs more than
2,200 individuals worldwide and has manufacturing facilities in several domestic
and international locations.

This document contains forward-looking statements, including statements relating
to, among other things, developments in the healthcare industry, third-party
reimbursement policies and practices, effectiveness of programs, future sales
and acceptance of the company's products and Power Programs(TM), integration of
the recent merger, new product development, anticipated cost savings and
regulatory requirements, and anticipated levels of earnings and revenues, all of
which are subject to change. Actual results may differ materially from those
described in any forward-looking statements. Additional information on potential
factors that could affect the company's financial results are included in the
reports filed with the SEC, including the reports on Form 10-K, 10-Q and 8-K.

SOURCE Respironics, Inc.